论文部分内容阅读
目的探讨纤维蛋白原(FIB)与2型糖尿病(T2DM)血管并发症发生的关系,为预防治疗和减少糖尿病慢性血管并发症的发生提供依据。方法选取120例T2DM患者为研究对象,根据血管并发症发生情况分为无血管并发症组30例(A组)、糖尿病微血管并发症组30例(B组)、糖尿病大血管并发症组30例(C组)、糖尿病微血管并发症合并糖尿病大血管并发症组30例(D组),分别检测各组受检者的血清纤维蛋白原(FIB)、糖化血红蛋白(Hb A1C)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、血肌酐(SCr)、血尿酸(SUA)、C反应蛋白(CRP)以及尿微量白蛋白,并对年龄、性别、糖尿病病程、有无高血压等指标进行多变量分析。结果与A组相比,其他3组血清FIB水平显著增加,差异有统计学意义(P<0.01)。多元逐步回归分析结果显示,FIB与年龄、有无高血压、尿微量白蛋白定量呈明显的相关(P<0.05,P<0.01)。结论血清FIB水平可作为T2DM患者血管并发症发生的评估指标,重视对FIB的干预治疗或能减少糖尿病血管并发症的发生。
Objective To investigate the relationship between fibrinogen (FIB) and vascular complications of type 2 diabetes mellitus (T2DM), and to provide evidence for the prevention and treatment of chronic vascular complications of diabetes mellitus. Methods A total of 120 T2DM patients were enrolled in this study. According to the incidence of vascular complications, 30 cases (group A) with no vascular complications, 30 cases with diabetic microangiopathy (group B) and 30 cases with diabetic macrovascular complications (Group C), 30 patients with macrovascular complication of diabetes mellitus (group D) with diabetic microangiopathy were enrolled in this study. Serum fibrinogen (FIB), glycosylated hemoglobin (Hb A1C), triglyceride TG, LDL-C, HDL-C, SCr, SUA, C-reactive protein (CRP) Urine microalbumin, and multivariate analysis of age, gender, duration of diabetes, with or without high blood pressure and other indicators. Results Compared with group A, the other three groups of serum FIB levels increased significantly, the difference was statistically significant (P <0.01). Multiple stepwise regression analysis showed that there was a significant correlation between FIB and age, with or without hypertension, and urine microalbumin (P <0.05, P <0.01). Conclusions Serum FIB levels can be used as an index to assess the occurrence of vascular complications in T2DM patients, and the emphasis is on the intervention treatment of FIBs or the reduction of the occurrence of diabetic vascular complications.